On April 27, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation reported major development regarding its tetra-valent, second-generation T-Cell Engager Program (the "Big BiTE") based on its TRBC platform technology, was presented at the poster session at the American Association of Cancer Research ("AACR") Annual Meeting 2026, which took place from April 17 – 22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HCW11-018b, the lead candidate of the "Big BiTE" program, is a tetra-valent T-cell engager designed to enhance anti-tumor activities and tolerability to treat a wide spectrum of solid tumors. The Company’s preclinical data showed HCW11-018b could significantly shrink well-established tumors and prevent cancer metastasis in xenograft animal models with broad coverage for human solid tumor indications.

The new data in the poster has revealed the mechanism of action that drives these results. HCW11-018b utilizes Cis-binding (or cis-interaction) to regulate immune cell reactivity that masks the receptors which prevent trans-binding and inhibit membrane flexibility. The data showed that HCW11-018b is only activated within the tumor microenvironment, which is expected to increase the efficacy and tolerability of this tetra-valent T Cell Engager against human tumor cells.

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, "HCW11-018b exhibits remarkable anti-tumor activities with high tolerability in animal models. With its streamlined GMP manufacturing process, the Company is vigorously -pursuing the clinical development path for solid tumors with particular focus on pancreatic and ovarian cancer. The IND application is projected to be filed in the first half of 2027."

The poster, entitled, "An innovative approach to improve bispecific T-cell engagers for solid tumor therapy," was presented by Dr. Wong at the AACR (Free AACR Whitepaper) Annual Meeting 2026. The poster is available on the Company’s investors’ website in the following link: View Source

(Press release, HCW Biologics, APR 27, 2026, View Source [SID1234664834])

On April 24, 2026 PDS Biotechnology presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, PDS Biotechnology, APR 24, 2026, View Source [SID1234664757])

On April 24, 2026 OmniAb, Inc. (NASDAQ: OABI) reported that management will be participating in three investor conferences over the coming weeks.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6 th.
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28 th.
Jefferies Global Healthcare Conference, June 2-4 at the Marriott Marquis in New York City. Management will present a corporate overview on Wednesday, June 3 rd at 4:55 p.m. Eastern time and will hold one-on-one meetings with investors.

(Press release, OmniAb, APR 24, 2026, View Source [SID1234664759])

On April 24, 2026 Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, reported the first public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform’s scientific community debut at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the first time the platform will be demonstrated live and without restriction to a global public audience of investors, researchers, and industry participants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

President and Chief Executive Officer Panna Sharma will lead the demonstration in real time — live, interactive, and unrehearsed — showing how withZeta.ai operates as a genuine AI co-scientist at the frontier of oncology drug discovery. Two identical sessions will be held to accommodate global time zones:

Morning Session: 8:30 AM ET — Register Here
Afternoon Session: 4:30 PM ET — Register Here
Each session will include a live platform walkthrough followed by an open Q&A with management.

From Scientific Validation to Public Stage

withZeta.ai made its scientific debut at AACR (Free AACR Whitepaper) 2026 — one of the world’s most rigorous forums for oncology and translational research — and was first unveiled at Nasdaq MarketSite, a globally recognized venue at the intersection of capital markets and innovation. April 30th represents a deliberate next step: opening the platform to the full public for the first time, with no gatekeeping, no curated excerpts, and no pre-recorded footage.

Attendees will watch in real time as the platform executes complex research workflows — synthesizing clinical, molecular, and scientific datasets simultaneously to generate insights and compress research timelines that historically required months of manual effort. This is not a product marketing event. It is a transparency event, and the platform will speak for itself.

A Platform Built for the Economics and Urgency of Rare Cancer

With the AI-driven drug discovery market projected to surpass $15 billion by 2030 and growing at over 30% annually, the industry is in the early stages of a structural transformation. Yet rare cancers remain the discipline’s most persistent blind spot — historically neglected not for lack of scientific interest, but because the economics and timelines of traditional development make them commercially unattractive.

withZeta.ai was purpose-built to close that gap. The platform integrates:

A proprietary rare cancer ontology spanning hundreds of cancer subtypes, structuring biological knowledge in a form that AI agents can actively reason across — not merely retrieve.
Multi-database querying across clinical trial registries, biomedical literature, and molecular datasets — simultaneously and in real time, not sequentially.
Advanced generative AI models for molecular design, ADMET prediction, blood-brain barrier permeability analysis, and structure-activity relationship (SAR) evaluation — capabilities embedded in the platform’s Ether0 generative chemistry architecture.
A scalable, subscription-based commercial model — with introductory, academic, and enterprise tiers — representing a non-dilutive, recurring revenue stream accessible to any researcher, institution, or biopharma organization globally.
Following its debut at Nasdaq MarketSite and AACR (Free AACR Whitepaper) 2026, Lantern is advancing withZeta.ai as both a scientific accelerator and a commercial growth engine — one that creates value for rare cancer patients, for research institutions, and for Lantern shareholders simultaneously.

"The rarest cancers have always faced the longest waits — not because the science is absent, but because the infrastructure to move at the speed of urgency has never existed. withZeta.ai changes that. It is not a search engine, not a literature tool, and not a chatbot with oncology data loaded in. It is a multi-agentic AI-powered co-scientist, forged from years of real clinical development, careful curation of knowledge-bases and exquisite disease models. It is capable of executing research workflows and drug development decision making and assessment in real time – things that would otherwise take months or longer. On April 30th, we are inviting the world to see it operate — live, unrehearsed, and without restriction."

— Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.

Webinar Access Details

Date: Thursday, April 30, 2026

Morning Session: 8:30 AM ET

Registration: Register for Morning Session
Afternoon Session: 4:30 PM ET

Registration: Register for Afternoon Session
Subscribe Now: withZeta.ai

(Press release, Lantern Pharma, APR 24, 2026, View Source;A-Platform-to-Conquer-Rare-Cancers-on-April-30-Following-AACR-2026-Scientific-Debut [SID1234664761])

On April 24, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Presentation:

Date and Time: Monday, April 27, 2026 at 8:00am ET

Toll Free: 1-877-407-9716

International: 1-201-493-6779

Conference ID: 13760371

Webcast Presentation: View Source;tp_key=efc315f5a6

A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the "Events" page under the Investors section of the Company’s website.

(Press release, Compass Therapeutics, APR 24, 2026, View Source [SID1234664762])